NICE appraisals should be everybody's business

BMJ

Volumn 334, Issue 7600, 2007, Pages 936-938

  Wells, Jane ^a   Cheong Leen, Claire ^b  

^a Berkshire West Primary Care Trust   (United Kingdom)

^b Department of Public Health Policy and Development   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PEGAPTANIB; RANIBIZUMAB; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CLINICAL PRACTICE; CLINICAL TRIAL; CONSULTATION; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; DRUG EFFICACY; FUNDING; HEALTH CARE; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HEALTH SERVICE; HUMAN; MEDICAL SOCIETY; METASTASIS; NATIONAL HEALTH SERVICE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RETINA MACULA DEGENERATION; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST BENEFIT ANALYSIS; DRUG APPROVAL; GOVERNMENT; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; PRESCRIPTION; PUBLIC RELATIONS; UNITED KINGDOM;

COST-BENEFIT ANALYSIS; DRUG APPROVAL; GOVERNMENT AGENCIES; GREAT BRITAIN; INTERPROFESSIONAL RELATIONS; PRACTICE GUIDELINES; PRESCRIPTIONS, DRUG; STATE MEDICINE; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 34249285561     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.39190.420081.94     Document Type: Review

References (15)

1. National Institute for Health and Clinical Excellence. About NICE. www.nice.org.uk/aboutNICE
2. Barrett A, Roques T, Small M, Smith RD. How much will Herceptin really cost? BMJ 2006; 333: 1118-20.
3. Raffle A. Lasting damage from the trastuzumab storm. BMJ 2006; 333: 761.
4. Roche UK. Summary of product characteristics: Herceptin. Roche UK, 2006. www.rocheuk.com/ProductDB/Documents/rx/spc/Herceptin_SPC.pdf
5. NICE. Final appraisal determination: trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer. London: NICE, 2006.
6. NICE. Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer. NICE technology appraisal guidance 107. London: NICE, 2006. www.nice.org.uk/page.aspx?o=TA107guidance
7. NICE. Guide to the single technology appraisal (STA) process. London: NICE, 2006. Available from www.nice.org.uk/page.aspx?o=STAprocessguide
8. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I,, et al Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72.
9. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE,, et al Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.
10. Joensuu H, Kellokumpu-Lehtinen P, Bono P, Alanko T, Kataja V, Asola R,, et al Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-20.
11. Pharmac. Herceptin. www.pharmac.govt.nz/herceptin.asp
12. Australian Department of Health and Ageing. PBAC recommendation to list Herceptin on the PBS. www.health.gov.au/internet/wcms/publishing.nsf/Content/herceptin-pbacdecision.htm
13. Department of Health. Health reform in England: update and commissioning framework. London: DoH 2006.
14. NICE. NICE welcomes referral of new work programme topics. Press release, 30 Aug 2006. www.nice.org.uk/page.aspx?o=358770
15. Chakravarthy U, Lim JI. Treatments for neovascular acute macular degeneration. BMJ 2007; 334: 269-70.